Genprex will share progress on two gene delivery strategies for its diabetes gene therapy program at the Future of Cell and Gene Therapy Symposium on November 17–18. Pier-Anne Lachance, Ph.D., Genprex’s senior director of Quality Control and Product Development, will present on the company’s work with adeno-associated virus (AAV) and non-viral lipid-based delivery technologies.
The presentation will address scientific, manufacturing, and product development challenges associated with both approaches. Genprex is pursuing gene therapy strategies aimed at restoring insulin-producing capabilities in patients with Type 1 and Type 2 diabetes. Its AAV-based candidate is designed to deliver the Pdx1 and MafA genes to the pancreas.
Alongside the viral approach, the company is investigating a lipid-based, non-viral delivery system that may allow for greater flexibility in administration, including repeat dosing. Both strategies are in preclinical development, and Genprex is evaluating them in parallel to optimize the program ahead of planned investigational new drug (IND)-enabling studies.
Source: drug-dev.com · Image: Andrew Byrnes, Ph.D.; Office of Cellular, Tissue and Gene Therapies, CBER (8003750281) by The U.S. Food and Drug Administration, Public domain, via Wikimedia Commons
Start your 7-day trial and see what the database can do →
